Alnylam Pharmaceuticals, Inc. (ALNY)
| Market Cap | 31.88B -47.8% |
| Revenue (ttm) | 4.80B +95.1% |
| Net Income | 774.71M |
| EPS | 5.62 |
| Shares Out | 133.81M |
| PE Ratio | 42.40 |
| Forward PE | 31.07 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,175,145 |
| Open | 246.99 |
| Previous Close | 249.99 |
| Day's Range | 237.44 - 247.43 |
| 52-Week Range | 197.81 - 495.55 |
| Beta | 0.30 |
| Analysts | Buy |
| Price Target | 371.35 (+55.85%) |
| Earnings Date | Oct 29, 2026 |
About ALNY
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amylo... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for ALNY stock is "Buy." The 12-month stock price target is $371.35, which is an increase of 55.85% from the latest price.
News
Alnylam Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
AMVUTTRA’s strong launch and robust clinical data have driven rapid growth, with a focus on expanding first-line use and broadening access. The pipeline features promising programs in Huntington’s disease, bleeding disorders, obesity, and hypertension, while international expansion and AI-driven innovation support long-term growth.
Alnylam Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
AMVUTTRA's cardiomyopathy launch has driven strong revenue and first-line market growth, supported by robust access and favorable clinical data. Competitive risks have lessened with tafamidis exclusivity extended and a failed rival trial, while international expansion and pipeline progress in mivelsiran, Huntington's, and bleeding disorders continue to advance.
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following ...
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 20...
Alnylam Pharmaceuticals Slides: ESC Congress Presentation
Alnylam Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 30, 2026.
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data across its...
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law
LOS ANGELES, Aug. 4, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnyl...
Alnylam Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 net product revenues surged 74% year-over-year to $1.2 billion, led by AMVUTTRA’s strong first-line growth and robust U.S. and international demand. 2026 revenue guidance was revised down by $200 million due to normalized second-line demand, but long-term growth targets remain intact, supported by favorable market dynamics and pipeline progress.
Alnylam Pharmaceuticals Earnings release: Q2 2026
Alnylam Pharmaceuticals released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Alnylam Pharmaceuticals Quarterly report: Q2 2026
Alnylam Pharmaceuticals has published its Q2 2026 quarterly earnings report on July 30, 2026.
Alnylam Pharmaceuticals Slides: Q2 2026
Alnylam Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended J...
Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter end...
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across its growing neuroscience portfolio at the Alzheimer...
AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.
AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.
Alnylam Pharmaceuticals Transcript: Study update
ALN-6400, an RNAi therapy targeting plasminogen, is advancing through phase I and II studies for HHT and VWD, aiming to provide durable, safe bleed protection with infrequent dosing. Early data show strong mechanistic rationale, promising safety, and potential to address significant unmet needs in these rare bleeding disorders.
Alnylam Pharmaceuticals Slides: Study update
Alnylam Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 25, 2026.
Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform
NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Komodo Health®, the leader in AI-powered healthcare intelligence, today announced an expanded strategic partnership with Alnylam Pharmaceuticals (Nasda...
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 10th series of “RNAi Roundtable” webin...
GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region
ATHENS, Greece--(BUSINESS WIRE)--GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region.
Alnylam Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management targets 25% revenue CAGR and 30% operating margin through 2030, driven by TTR franchise leadership and pipeline diversification. AMVUTTRA leads near-term growth, with nucresiran and other assets advancing. U.S. access remains strong, and R&D investment is prioritized.
Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500
The index added two companies on Friday, but more are likely to be added in the near future.
Alnylam, Inceptive sign up to $2 billion AI drug discovery deal
Alnylam Pharmaceuticals said on Wednesday it has teamed up with artificial-intelligence biotech Inceptive in a deal worth up to $2 billion to use AI to speed up discovery of RNA-based medicines.
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
CAMBRIDGE, Mass. & PALO ALTO, Calif.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Inceptive Nucleics, Inc., which builds foundation models...